Regulation of proliferation, apoptosis and cell cycle in gastrointestinal disorders

Current Opinion in Pharmacology

Volumn 9, Issue 6, 2009, Pages 708-714

  Jackson, Lindsey N ^a   Evers, B Mark ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; ANTIINFLAMMATORY AGENT; CLOTRIMAZOLE; CROMOGLYCATE DISODIUM; CURCUMIN; ERITORAN; ETANERCEPT; FLUOROURACIL; GALECTIN 2; GALECTIN 4 ANTIBODY; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; LIPOCORTIN 1; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OXYMATRINE; POMIFERIN; PYRROLIDINE DITHIOCARBAMATE; RESVERATROL; STEROID; SULFORAPHANE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANILLIN; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; COLITIS; COLON CANCER; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INFLAMMATION; DRUG TARGETING; ENTERITIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK REDUCTION; ULCERATIVE COLITIS;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MODELS, IMMUNOLOGICAL;

EID: 70449506758     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.06.024     Document Type: Review

References (60)

1. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287 (2004) G7-G17
2. Lichtenstein G.R. Reduction of colorectal cancer risk in patients with Crohn's disease. Rev Gastroenterol Disord 2 Suppl. 2 (2002) S16-S24
3. Jackson L., and Evers B.M. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 130 (2006) 39-65
4. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
5. Harris A., Feller E.R., and Shah S.A. Medical therapy of IBD in 2009. Med Health R I 92 (2009) 78-81
6. Owczarek D., Cibor D., Szczepanek M., and Mach T. Biological therapy of inflammatory bowel disease. Pol Arch Med Wewn 119 (2009) 84-88
7. Hokama A., Mizoguchi E., and Mizoguchi A. Roles of galectins in inflammatory bowel disease. World J Gastroenterol 14 (2008) 5133-5137
8. van der Leij J., van den Berg A., Harms G., Eschbach H., Vos H., Zwiers P., van Weeghel R., Groen H., Poppema S., and Visser L. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol 44 (2007) 506-513. The authors describe the production of a leucine-zipper based stable galectin-1 homodimer (dGal) and examine its effect on human peripheral blood monocyte cells from healthy volunteers in vitro; they find that treatment with dGal attenuates IL-2 production and induces IL-10 and IL-1β production, suggesting that it may serve as a treatment for chronic inflammatory diseases.
9. Paclik D., Berndt U., Guzy C., Dankof A., Danese S., Holzloehner P., Rosewicz S., Wiedenmann B., Wittig B.M., Dignass A.U., et al. Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J Mol Med 86 (2008) 1395-1406. Using acute and chronic murine colitis models, the authors determined galectin-2 expression and binding profiles by immunohistochemistry; they next treat mice with galectin-2 and find that its administration leads to apoptosis of mucosal T cells, ameliorating colitis.
10. Hokama A., Mizoguchi E., Sugimoto K., Shimomura Y., Tanaka Y., Yoshida M., Rietdijk S.T., de Jong Y.P., Snapper S.B., Terhorst C., et al. Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20 (2004) 681-693. Utilizing an antigen-screening approach, the authors identify an epithelial lectin, galectin-4, that specifically stimulates IL-6 production by CD4(+) T cells under intestinal inflammatory conditions, exacerbating chronic colitis and delaying recovery from acute intestinal injury.
11. Fries W., Muja C., Crisafulli C., Costantino G., Longo G., Cuzzocrea S., and Mazzon E. Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci 5 (2008) 169-180
12. Fries W., Muja C., Crisafulli C., Cuzzocrea S., and Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol 294 (2008) G938-G947
13. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15 (2009) 103-113. The authors demonstrate that besides its role in enhancing proliferation of tumor-initiated cells, IL-6 produced by myeloid cells protects normal and premalignant intestinal epithelial cells from apoptosis; furthermore, they demonstrate that the effects of IL-6 are mediated by the transcription factor Stat3, whose ablation in intestinal epithelial cells portends a significant impact on tumorigenesis.
14. Gukovsky I., Reyes C.N., Vaquero E.C., Gukovskaya A.S., and Pandol S.J. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol 284 (2003) G85-G95
15. Wang X., Wang Q., Ives K.L., and Evers B.M. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 12 (2006) 5346-5355
16. Binion D.G., Otterson M.F., and Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57 (2008) 1509-1517
17. Babbin B.A., Laukoetter M.G., Nava P., Koch S., Lee W.Y., Capaldo C.T., Peatman E., Severson E.A., Flower R.J., Perretti M., et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol 181 (2008) 5035-5044. Using AnxA1 (-/-) mice, the authors demonstrate that AnxA1-deficient animals exhibit increased susceptibility to dextran sulfate sodium (DSS)-induced colitis, and that administration of the ALX/FPRL-1 agonist, 15-epi-lipoxin A4, abrogates the development colitis.
18. Perretti M., and D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9 (2009) 62-70
19. Solito E., Kamal A., Russo-Marie F., Buckingham J.C., Marullo S., and Perretti M. A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J 17 (2003) 1544-1546
20. Scannell M., Flanagan M.B., deStefani A., Wynne K.J., Cagney G., Godson C., and Maderna P. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 178 (2007) 4595-4605
21. Maderna P., Yona S., Perretti M., and Godson C. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J Immunol 174 (2005) 3727-3733
22. Yazid S., Solito E., Christian H., McArthur S., Goulding N., and Flower R. Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. Biochem Pharmacol 77 (2009) 1814-1826
23. D'Acquisto F., Merghani A., Lecona E., Rosignoli G., Raza K., Buckley C.D., Flower R.J., and Perretti M. Annexin-1 modulates T-cell activation and differentiation. Blood 109 (2007) 1095-1102
24. Gustin J.A., Ozes O.N., Akca H., Pincheira R., Mayo L.D., Li Q., Guzman J.R., Korgaonkar C.K., and Donner D.B. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 279 (2004) 1615-1620
25. Wu S.L., Chen J.C., Li C.C., Lo H.Y., Ho T.Y., and Hsiang C.Y. Vanillin Improves and Prevents Trinitrobenzene Sulfonic Acid-Induced Colitis in Mice. J Pharmacol Exp Ther 330 (2009) 370-376
26. Thapa D., Lee J.S., Park M.A., Cho M.Y., Park Y.J., Choi H.G., Jeong T.C., and Kim J.A. Inhibitory effects of clotrimazole on TNF-alpha-induced adhesion molecule expression and angiogenesis. Arch Pharm Res 32 (2009) 593-603
27. Thapa D., Lee J.S., Park S.Y., Bae Y.H., Bae S.K., Kwon J.B., Kim K.J., Kwak M.K., Park Y.J., Choi H.G., et al. Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner. J Pharmacol Exp Ther 327 (2008) 353-364
28. Martin A.R., Villegas I., Sanchez-Hidalgo M., and de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 147 (2006) 873-885
29. Roy P., Kalra N., Nigam N., George J., Ray R.S., Hans R.K., Prasad S., and Shukla Y. Resveratrol enhances ultraviolet B-induced cell death through nuclear factor-kappaB pathway in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 384 (2009) 215-220
30. Mi Jeong S., Davaatseren M., Kim W., Sung Kwang P., Kim S.H., Haeng Jeon H., Myung Sunny K., Kim Y.S., and Dae Young K. Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NF-kappaB activation in RAW 264.7 cells. Int Immunopharmacol 9 (2009) 319-323
31. Yang Y.T., Weng C.J., Ho C.T., and Yen G.C. Resveratrol analog-3,5,4′-trimethoxy-trans-stilbene inhibits invasion of human lung adenocarcinoma cells by suppressing the MAPK pathway and decreasing matrix metalloproteinase-2 expression. Mol Nutr Food Res 53 (2009) 407-416
32. Mariadason J.M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 3 (2008) 28-37
33. Kim Y.S., Tsao D., Siddiqui B., Whitehead J.S., Arnstein P., Bennett J., and Hicks J. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer 45 (1980) 1185-1192
34. Gum J.R., Kam W.K., Byrd J.C., Hicks J.W., Sleisenger M.H., and Kim Y.S. Effects of sodium butyrate on human colonic adenocarcinoma cells. Induction of placental-like alkaline phosphatase. J Biol Chem 262 (1987) 1092-1097
35. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 (1997) 595-606
36. Ammanamanchi S., Freeman J.W., and Brattain M.G. Acetylated sp3 is a transcriptional activator. J Biol Chem 278 (2003) 35775-35780
37. Marzio G., Wagener C., Gutierrez M.I., Cartwright P., Helin K., and Giacca M. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275 (2000) 10887-10892
38. Tomita A., Towatari M., Tsuzuki S., Hayakawa F., Kosugi H., Tamai K., Miyazaki T., Kinoshita T., and Saito H. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene 19 (2000) 444-451
39. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., and Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281 (2006) 13548-13558
40. Riggs M.G., Whittaker R.G., Neumann J.R., and Ingram V.M. n-Butyrate causes histone modification in HeLa and friend erythroleukaemia cells. Nature 268 (1977) 462-464
41. Dashwood R.H., and Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 17 (2007) 363-369
42. Shen G., Khor T.O., Hu R., Yu S., Nair S., Ho C.T., Reddy B.S., Huang M.T., Newmark H.L., and Kong A.N. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 67 (2007) 9937-9944
43. Son I.H., Chung I.M., Lee S.I., Yang H.D., and Moon H.I. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett 17 (2007) 4753-4755
44. Tumber A., Collins L.S., Petersen K.D., Thougaard A., Christiansen S.J., Dejligbjerg M., Jensen P.B., Sehested M., and Ritchie J.W. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60 (2007) 275-283
45. Karagiannis T.C., and El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25 (2006) 3885-3893
46. Schulzke J.D., Bojarski C., Zeissig S., Heller F., Gitter A.H., and Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci 1072 (2006) 288-299
47. Begue B., Wajant H., Bambou J.C., Dubuquoy L., Siegmund D., Beaulieu J.F., Canioni D., Berrebi D., Brousse N., Desreumaux P., et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 130 (2006) 1962-1974
48. Otte J.M., Werner I., Brand S., Chromik A.M., Schmitz F., Kleine M., and Schmidt W.E. Human beta defensin 2 promotes intestinal wound healing in vitro. J Cell Biochem 104 (2008) 2286-2297
49. Tanaka H., Hoshikawa Y., Oh-hara T., Koike S., Naito M., Noda T., Arai H., Tsuruo T., and Fujita N. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res 7 (2009) 557-569
50. Evans M.E., Jones D.P., and Ziegler T.R. Glutamine inhibits cytokine-induced apoptosis in human colonic epithelial cells via the pyrimidine pathway. Am J Physiol Gastrointest Liver Physiol 289 (2005) G388-G396
51. Fan H., Chen R., Shen L., Lv J., Xiong P., Shou Z., and Zhuang X. Oxymatrine improves TNBS-induced colitis in rats by inhibiting the expression of NF-kappaB p65. J Huazhong Univ Sci Technolog Med Sci 28 (2008) 415-420
52. Zhao J., Yu S., Tong L., Zhang F., Jiang X., Pan S., Jiang H., and Sun X. Oxymatrine attenuates intestinal ischemia/reperfusion injury in rats. Surg Today 38 (2008) 931-937
53. Fukata M., and Abreu M.T. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 35 (2007) 1473-1478
54. Chang Y.C., Kao W.C., Wang W.Y., Yang R.B., and Peck K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J (2009). Using a novel molecular evolution strategy combining immunoprecipitation with the evolution of ligands by exponential enrichment (SELEX), the authors develop a method to facilitate the screening of high-affinity aptamers for TLR2; functional aptamers were then characterized using NF-κB reporter assays. One aptamer, AP177, significantly inhibits NF-κB activity, suppressing the secretion of cytokines by >80%, indicating therapeutic potential in the treatment of diseases characterized by a dysregulation of TLR2 signaling.
55. Yao H., Felfly H., Wang J., Zhou D., and Haddad G.G. DIDS protects against neuronal injury by blocking Toll-like receptor 2 activated-mechanisms. J Neurochem 108 (2009) 835-846
56. Ungaro R., Fukata M., Hsu D., Hernandez Y., Breglio K., Chen A., Xu R., Sotolongo J., Espana C., Zaias J., et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 296 (2009) G1167-G1179. The authors utilize two murine models of inflammatory bowel disease to determine the effects of TLR4/MD-2 antibody administration during induction or recovery from colitis; they find that Anti-TLR4 Ab treatment decreases macrophage and dendritic cell infiltrate and reduces IL-6 and TNF-α expression during initiation of colitis, but by contrast, treatment during recovery from colitis results in defective mucosal healing with decreased expression of COX-2, prostaglandin E2, and amphiregulin.
57. Rossignol D.P., Wong N., Noveck R., and Lynn M. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. Innate Immun 14 (2008) 383-394
58. Vijay-Kumar M., Sanders C.J., Taylor R.T., Kumar A., Aitken J.D., Sitaraman S.V., Neish A.S., Uematsu S., Akira S., Williams I.R., et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 117 (2007) 3909-3921
59. Gewirtz A.T., Vijay-Kumar M., Brant S.R., Duerr R.H., Nicolae D.L., and Cho J.H. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1157-G1163
60. Lunardi C., Bason C., Dolcino M., Navone R., Simone R., Saverino D., Frulloni L., Tinazzi E., Peterlana D., Corrocher R., et al. Antiflagellin antibodies recognize the autoantigens Toll-Like Receptor 5 and Pals 1-associated tight junction protein and induce monocytes activation and increased intestinal permeability in Crohn's disease. J Intern Med 265 (2009) 250-265